Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.
Julie M FoxMichael BradyHannah AlexanderOlubanke DaviesNicola RobinsonMathew PaceLaura ElseJohn CasonSaye KhooDavid BackSarah FidlerJohn FraterPublished in: Infectious diseases and therapy (2016)
The use of antiretrovirals as pre-exposure prophylaxis (PrEP) is highly efficacious in HIV prevention. The World Health Organization recently recommended Truvada(®) (Gilead Sciences, Inc.) or tenofovir disoproxil fumarate (TDF) for high-risk individuals, with limited data for single-agent TDF PrEP in men who have sex with men (MSM). We report two cases of TDF PrEP failure in MSM who had received long-term TDF for hepatitis B infection and had therapeutic levels of drug immediately after HIV acquisition. Rapid antiretroviral intensification at diagnosis of acute HIV infection failed to limit immune dysfunction or prevent the establishment of a viral reservoir.
Keyphrases
- men who have sex with men
- hiv positive
- hiv testing
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- sars cov
- hiv infected patients
- hiv aids
- liver failure
- drug induced
- electronic health record
- emergency department
- intensive care unit
- machine learning
- hepatitis b virus
- respiratory failure
- aortic dissection
- hepatitis c virus
- adverse drug
- deep learning
- acute respiratory distress syndrome